Genomic profiling of blood and bone marrow samples from children and young adults with blood cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on genomic profiling and the collection of blood and bone marrow specimens from pediatric patients diagnosed with leukemia, myelodysplastic syndromes, or myeloproliferative syndromes. Participants will have their samples analyzed to understand the genetic factors contributing to their diseases, which may influence treatment decisions. The study aims to enroll approximately 100 patients annually across eight medical centers in the United States, utilizing samples obtained during clinical procedures. The genomic data collected will be shared with treating oncologists to potentially guide therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age: birth to \< 30 years of age
* Diagnosis:

  \-- Patient with acute leukemia, chronic leukemia, MDS/AML, myelodysplastic syndrome or myeloproliferative syndromes. Disease can be newly diagnosed or relapsed/refractory.
* Pathology Criteria:

  \-- Histologic confirmation of leukemia or myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS) at the time of diagnosis or recurrence
* Specimen Criteria:

  * Sufficient sample available for genomic profiling OR bone marrow aspirate/blood draw planned for clinical care which is anticipated to allow collection of minimum specimen for testing (See Section 6.1 for description of specimen requirements)

Exclusion Criteria:

\- Insufficient leukemia or MDS specimen available for profiling from diagnosis or recurrence (See Section 6.1); or bone marrow evaluations NOT planned for clinical care; or peripheral blast percentage \<20%, or clinical blood draw not planned

Where it's running

• Connecticut Children's Medical Center
  Hartford, Connecticut, United States Recruiting
• Maine Medical Center
  Portland, Maine, United States Recruiting
• Dartmouth-Hitchcock
  Lebanon, New Hampshire, United States Recruiting
• Albany Medical Center
  Albany, New York, United States Recruiting
• Lifespan Cancer Institute
  Providence, Rhode Island, United States Recruiting
• University of Vermont Medical Center
  Burlington, Vermont, United States Recruiting

Study contacts

• Principal investigator: Yana Pikman, MD — Dana-Farber Cancer Institute
• Study coordinator: Yana Pikman, MD
• Email: yana_pikman@dfci.harvard.edu
• Phone: (617) 632-4754

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cord blood transplant for children and young adults with blood cancers.

  This study will test whether a cord blood transplant given as a first or second transplant can help children and young adults with leukemia, myelodysplasia, or lymphoma who lack a matched donor.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT07566377

• Improving outcomes for stem cell transplant patients using an intervention website

  This study is testing if a special website can help adults with blood cancer feel better and improve their quality of life after a stem cell transplant compared to a regular educational website.

  Recruiting at 3 sites Northwestern University · Washington D.C., District of Columbia and 2 other locations · NCT06960993

• Testing BH-30236 for relapsed or refractory acute myelogenous leukemia and higher-risk myelodysplastic syndrome

  This study is testing a new drug called BH-30236 to see if it can help adults with relapsed or hard-to-treat acute myelogenous leukemia or higher-risk myelodysplastic syndrome.

  Recruiting at 13 sites Phase 1 BlossomHill Therapeutics · Duarte, California and 12 other locations · NCT06501196

• Home blood transfusions for people with advanced blood cancers in hospice

  The study will test whether offering home blood transfusions to adults with advanced or relapsed blood cancers who are eligible for hospice helps improve quality of life, mood, and end-of-life care.

  Recruiting at 2 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06487247

• CIML NK cell therapy to prevent relapse after stem cell transplant

  This study is testing if a new type of immune cell therapy can help prevent relapse in people with certain blood cancers after they receive a stem cell transplant.

  Recruiting Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06138587

• Impact of Leukemia and Lymphoma Society services on blood cancer patients

  This study is testing how the services provided by the Leukemia and Lymphoma Society can help people with blood cancers feel better and manage their care over six months.

  Recruiting University of Miami · Miami, Florida and 2 other locations · NCT05745285

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.